COVAXX has announced a global logistics partnership with Maersk. The agreement lays out a framework for all transportation and supply chain services that will be needed to deliver COVAXX’s vaccine candidate UB-612 around the world, once approved by regulatory authorities. Financial terms of the agreement are not disclosed. COVAXX is developing UB-612 using a high precision, synthetic peptide platform to activate both B-cell and T-cell arms. The investigational vaccine is designed to mimic natural biology and preclinical studies have shown high immunogenicity and levels of neutralising titers against SARS-CoV-2. The technology platform has been successful in commercialising blood diagnostics as well as safe and effective vaccines for infectious disease in animal health and has been tested in numerous clinical trials for other indications to date.
“The COVAXX vaccine is unique in that it can be stored in the fridge you have at home, moved in the same trucks that deliver groceries and administered anywhere you can get a flu shot.” – Lou Reese, Co-Chief Executive Officer of COVAXX.
“Our team, which now proudly includes Maersk, is committed to addressing the needs of countries where the greatest unmet needs exist today,” said Mei Mei Hu, co-Chief Executive Officer of COVAXX. “To do what is in the best interests of society at this time of the global health crisis, we are aligning with the strongest leaders in their respective industries to meet the large-scale demand and compliance requirements that we expect. It is not enough to focus on vaccine development and approvals. We must work in parallel to establish the infrastructure and partners with the strongest capabilities, like Maersk, to safely deliver our vaccine around the world.”
“Efficient and safe delivery of COVID-19 vaccines around the world is the most urgent logistics challenge we face today. A.P. Moller – Maersk is committed to working closely with COVAXX to ens